Dive into the Biopharma Space

Private bio/pharma funding in 2025 totaled approximately $40.0 B  across 1,045 private funding events, slightly below 2024’s $40.4 B , but substantially below 2024’s 1,367  deals (FN1). Activity was heavily front-loaded, with January 2025  alone accounting for $6.3 B  and 138 deals , the single most active month of the year.  After a mid-year lull in deal volume and capital deployment, the market saw modest late-year momentum, particularly in October ($6.0 B) and December ($3

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? 1. Public smid-cap biotech stocks soared in the 2nd half of 2025; 2. Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year; 3. Once the biotech IPO market opens, private funding should follow in subsequent quarters 1. Public smid-cap biotech stocks soared in the 2

Europe has rapidly become one of the world’s most dynamic regions for genetic analysis, sequencing technologies, and data-driven precision medicine. From liquid biopsies and transplant monitoring to next-generation bioinformatics platforms, a wave of innovative companies is redefining how genetic data is generated, interpreted, and applied in real clinical settings. At BiopharmIQ , we track 141 active European companies operating in genetic analysis, sequencing, and enablin

Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease. Here are 10 companies to watch in 2025 , each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

Southern California has long been known for its beaches and biotech, and nowhere is the region’s innovation more evident than in its antibody ecosystem . From San Diego’s wet labs  to Pasadena’s protein engineers , the area has become a proving ground for companies blending creativity, capital, and clinical progress. At BiopharmIQ, we’ve tracked more than a hundred SoCal bio/pharma's developing antibody-based drugs, and we’ve handpicked 10 companies to watch in 2025 , chosen

" Private bio/pharma funding activity strengthened in September, reaching its highest level since early 2025 and reflecting a gradual re-acceleration in deal flow. " September 2025 marks the end of the third quarter with a significant uptick in deal activity , even though total dollars raised remain below early-year highs. The market continues to favor non-dilutive funding and smaller financings, with grants leading by deal count  and early-stage rounds bouncing back  from th

"Private bio/pharma funding rebounded in value in August, though deal counts remain subdued." August 2025 marked the seventh consecutive...

Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic...

Cell therapy continues to be one of the most dynamic segments of biotech and pharma financing in 2025. From oncology to neurology,...

2025 Bio/Pharma Funding Trends: July’s Update

“Bio/pharma funding deal data in H1 2025 reveals a troubling downward shift starting in February.” Investment in bio/pharma was down in...

The global biotech and pharmaceutical landscape in 2024 continued to attract significant investment, with our BiopharmIQ system capturing...

The latest wave of new and emerging biologic companies in 2024 highlights a continued diversity of technology areas with a strong focus...

Bio/pharma continued to attract investments in December 2024 to support the discovery and development of new bio/pharma therapeutics. In...

We analyzed biotech funding data on our online biopharmIQ platform to identify companies who had early-stage (Angel/Pre-Seed, Seed,...

We analyzed biotech funding data on our online biopharmIQ platform  to identify companies who had late-stage* biotech funding events...

A valuable signal (i.e. hot lead) for vendors is when a potential customer closes a funding round. We identify these funding events and...

New cell & gene therapy (CGT) companies continue to emerge in 2024. To detect these new/emerging CGT companies, every workday, our team...

We analyzed biotech funding data on our online biopharmIQ platform  to identify companies who had early-stage (Angel/Pre-Seed, Seed,...

As we mentioned in our prior post , the vast majority of new/newly emerging biotech companies that we identified thus far in 2024, are...